Results 261 to 270 of about 5,785,146 (400)

Advances in isoxazole chemistry and their role in drug discovery. [PDF]

RSC Adv
Martis GJ, Gaonkar SL.
europepmc   +1 more source

Knockout of the mitoribosome rescue factors Ict1 or Mtrfr is viable in zebrafish but not mice: compensatory mechanisms underlying each factor's loss

FEBS Open Bio, EarlyView.
Mitochondria contain two mitoribosome rescue factors, ICT1 and MTRFR (C12orf65). ICT1 also functions as a mitoribosomal protein in mice and humans, and its loss is lethal. Although Mtrfr knockout mice could not be generated, knockout zebrafish lines for ict1 and mtrfr were established.
Nobukazu Nameki, Chika Tomisawa, Soichiro Hoshino, Hidehiko Shimizu, Masashi Abe, Sho Arai, Kanako Kuwasako, Naoki Asakawa, Yusuke Inoue, Takuro Horii, Izuho Hatada, Masakatsu Watanabe   +11 more
wiley   +1 more source

Editorial: Debates in experimental pharmacology and drug discovery 2023: innovative approaches to chronic kidney disease drug discovery, identification of targets and safety assessment. [PDF]

Front Pharmacol
Khan MAH, Ameer OZ, Goorani S, Salman IM.   +3 more
europepmc   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

FEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng, Eric Feng, Tracy Berg, Isabella S. Nguyen, Lilac G. Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li, Ilsa Coleman, Peter S. Nelson, Martin Sjöström, Shuang G. Zhao   +13 more
wiley   +1 more source

Special Issue "Antifungal Drug Discovery: Progresses, Challenges, Opportunities". [PDF]

Int J Mol Sci
Biersack B.
europepmc   +1 more source

An efficient strategy for producing RNA‐free Nucleocapsid protein of SARS‐CoV‐2 for biochemical and structural investigations

FEBS Open Bio, EarlyView.
Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley   +1 more source

Capsule neural network and its applications in drug discovery. [PDF]

iScience
Wang Y, Wang B, Zou J, Wu A, Liu Y, Wan Y, Luo J, Wu J.   +7 more
europepmc   +1 more source

Risk analysis of the Unity 1.5T MR‐Linac adapt‐to‐shape workflow

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Background and Purpose The adapt‐to‐shape (ATS) workflow on the Unity MR‐Linac (Elekta AB, Stockholm, Sweden) allows for full replanning including recontouring and reoptimization5. Additional complexity to this workflow is added when the adaptation involves the use of MIM Maestro (MIM Software, Cleveland, OH) software in conjunction with ...
Jiayi Liang, Eric Aliotta, Neelam Tyagi, Paola Godoy Scripes, Nicolas Côté, Ergys Subashi, Qijie Huang, Lian Sun, Ching‐Yun Chan, Angela Ng, Theresa Wunner, Victoria Brennan, Kaveh Zakeri, James Mechalakos   +13 more
wiley   +1 more source

Artificial intelligence approaches for anti-addiction drug discovery.

Digit Discov
Chen D, Jiang J, Hayes N, Su Z, Wei GW.
europepmc   +1 more source

Ascertaining a Structural Basis in Drug Discovery and Development. [PDF]

J Med Chem
Heppner DE.
europepmc   +1 more source